Table 3 Anti-SARS-CoV-2 antibody (IgG) profile in study participants at baseline (days 0–5) and one-month follow-up (days 28–35)
Antibodies | Baseline | One-month follow-up | Change from baseline | ||||||
|---|---|---|---|---|---|---|---|---|---|
Probiotic group (n = 22) | Placebo group (n = 22) | P –value | Probiotic group (n = 22) | Placebo group (n = 22) | P -value | Probiotic group (n = 22) | Placebo group (n = 22) | P -value | |
NCP, ratio, units, median (IQR) | 0.20 (0.10–1.86) | 0.44 (0.28–2.15) | 0.080a | 5.25 (3.12–6.93) | 4.13 (3.76–5.20) | 0.478 0.178b | 3.64 (1.64–6.11) | 2.97 (1.61–4.10) | 0.299 |
RBD/S1, BAU/ml, median (IQR) | 35.2 (3.2–102.4) | 62.4 (3.2–198.4) | 0.357 | 312.0 (240.0–384.0) | 230.4 (176.0–384.0) | 0.072 0.012b | 225.9 (127.7–317.4) | 105.6 (67.8–189.4) | 0.012 |